Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 532
- Registration Number
- NCT02906917
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: placebo
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 703
- Registration Number
- NCT02906930
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT02877355
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 187
- Registration Number
- NCT02870231
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT02868229
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 711
- Registration Number
- NCT02863419
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 822
- Registration Number
- NCT02863328
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 504
- Registration Number
- NCT02849080
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Rize, Turkey
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT02845219
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT02844790
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath